Informações:
Falhas:
ID
31188
Descrição
Study to Evaluate SID 530 Compared to Taxotere; ODM derived from: https://clinicaltrials.gov/show/NCT00931008
Link
https://clinicaltrials.gov/show/NCT00931008
Palavras-chave
Versões (1)
- 25.07.18 25.07.18 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
25. Juli 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Non-Small Cell Lung Cancer NCT00931008
Eligibility Non-Small Cell Lung Cancer NCT00931008
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer NCT00931008
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Informed Consent
Item
has provided written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
is at least 18 years of age
boolean
C0001779 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma | Locally advanced breast cancer | Secondary malignant neoplasm of female breast
Item
has histologically or cytologically confirmed non-small cell lung (nsclc) or breast cancer (bc) that is locally advanced or metastatic
boolean
C0007131 (UMLS CUI [1])
C3495949 (UMLS CUI [2])
C0346993 (UMLS CUI [3])
C3495949 (UMLS CUI [2])
C0346993 (UMLS CUI [3])
Docetaxel Dose Planned
Item
has at least two planned consecutive 21-day cycles with 75 mg/m2 docetaxel monotherapy
boolean
C0246415 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
C0178602 (UMLS CUI [1,2])
C1301732 (UMLS CUI [1,3])
Life Expectancy
Item
has a life expectancy of at least 3 months
boolean
C0023671 (UMLS CUI [1])
ECOG performance status
Item
has eastern cooperative oncology group performance scale (ecog ps) is in the range of 0-2 at the time of randomization
boolean
C1520224 (UMLS CUI [1])
Laboratory Results
Item
has the proper laboratory values within 1 week prior to randomization
boolean
C1254595 (UMLS CUI [1])
Childbearing Potential Serum pregnancy test negative
Item
has negative serum pregnancy test within 1 week before first study drug administration (for women of childbearing potential, only)
boolean
C3831118 (UMLS CUI [1,1])
C0430061 (UMLS CUI [1,2])
C0430061 (UMLS CUI [1,2])
Childbearing Potential Contraceptive methods
Item
is willing to practice medically accepted contraception (if the risk of conception exists) throughout the study period (from screening until the final visit)
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,2])
Exclusion Criteria Study Subject
Item
exclusion criteria:study participants
boolean
C0680251 (UMLS CUI [1,1])
C0681850 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,2])
Chemotherapy
Item
has had any chemotherapy within 4 weeks before date of first study treatment
boolean
C0392920 (UMLS CUI [1])
Adverse effects Severe Docetaxel | Severe allergy Docetaxel | Adverse effects Severe Drug Formulation Polysorbate 80 | Severe allergy Drug Formulation Polysorbate 80 | Adverse effects Severe Hydroxypropyl betadex | Severe allergy Hydroxypropyl betadex | Adverse effects Severe Povidone | Severe allergy Povidone | Treatment Discontinuation Required
Item
has experienced severe side effects from (or severe hypersensitivity to) prior docetaxel treatment (or other drugs formulated with polysorbate 80, hydroxypropylbetadex, or povidone) such that discontinuation of the treatment was required
boolean
C0879626 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0246415 (UMLS CUI [1,3])
C2945656 (UMLS CUI [2,1])
C0246415 (UMLS CUI [2,2])
C0879626 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0524527 (UMLS CUI [3,3])
C0032601 (UMLS CUI [3,4])
C2945656 (UMLS CUI [4,1])
C0524527 (UMLS CUI [4,2])
C0032601 (UMLS CUI [4,3])
C0879626 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C0046237 (UMLS CUI [5,3])
C2945656 (UMLS CUI [6,1])
C0046237 (UMLS CUI [6,2])
C0879626 (UMLS CUI [7,1])
C0205082 (UMLS CUI [7,2])
C0032856 (UMLS CUI [7,3])
C2945656 (UMLS CUI [8,1])
C0032856 (UMLS CUI [8,2])
C0087111 (UMLS CUI [9,1])
C0457454 (UMLS CUI [9,2])
C1514873 (UMLS CUI [9,3])
C0205082 (UMLS CUI [1,2])
C0246415 (UMLS CUI [1,3])
C2945656 (UMLS CUI [2,1])
C0246415 (UMLS CUI [2,2])
C0879626 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0524527 (UMLS CUI [3,3])
C0032601 (UMLS CUI [3,4])
C2945656 (UMLS CUI [4,1])
C0524527 (UMLS CUI [4,2])
C0032601 (UMLS CUI [4,3])
C0879626 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C0046237 (UMLS CUI [5,3])
C2945656 (UMLS CUI [6,1])
C0046237 (UMLS CUI [6,2])
C0879626 (UMLS CUI [7,1])
C0205082 (UMLS CUI [7,2])
C0032856 (UMLS CUI [7,3])
C2945656 (UMLS CUI [8,1])
C0032856 (UMLS CUI [8,2])
C0087111 (UMLS CUI [9,1])
C0457454 (UMLS CUI [9,2])
C1514873 (UMLS CUI [9,3])
Dexamethasone allergy
Item
has a history of hypersensitivity to dexamethasone
boolean
C0571611 (UMLS CUI [1])
Pregnancy | Lactation | Breast Feeding
Item
is pregnant, lactating, or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0022925 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
C0022925 (UMLS CUI [2])
C0006147 (UMLS CUI [3])
CYP3A4 Inducer | CYP3A4 Inhibitor | Other Coding
Item
is taking one or more compounds that induce, inhibit, or are metabolized by cytochrome p450 3a4
boolean
C3830625 (UMLS CUI [1])
C3830624 (UMLS CUI [2])
C3846158 (UMLS CUI [3])
C3830624 (UMLS CUI [2])
C3846158 (UMLS CUI [3])
Study Subject Participation Status | Therapy, Investigational
Item
has had treatment in another clinical study within the past 30 days
boolean
C2348568 (UMLS CUI [1])
C0949266 (UMLS CUI [2])
C0949266 (UMLS CUI [2])
Medical condition Completion of clinical trial Excluded | Medical condition Informed Consent Excluded | Mental condition Completion of clinical trial Excluded | Mental condition Informed Consent Excluded
Item
has medical or psychological conditions that would not permit the study participant to complete the study or sign informed consent
boolean
C3843040 (UMLS CUI [1,1])
C2732579 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0021430 (UMLS CUI [2,2])
C0332196 (UMLS CUI [2,3])
C3840291 (UMLS CUI [3,1])
C2732579 (UMLS CUI [3,2])
C0332196 (UMLS CUI [3,3])
C3840291 (UMLS CUI [4,1])
C0021430 (UMLS CUI [4,2])
C0332196 (UMLS CUI [4,3])
C2732579 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0021430 (UMLS CUI [2,2])
C0332196 (UMLS CUI [2,3])
C3840291 (UMLS CUI [3,1])
C2732579 (UMLS CUI [3,2])
C0332196 (UMLS CUI [3,3])
C3840291 (UMLS CUI [4,1])
C0021430 (UMLS CUI [4,2])
C0332196 (UMLS CUI [4,3])
Protocol Compliance Unlikely
Item
is unlikely to comply with the protocol requirements, instructions and study-related restrictions
boolean
C0525058 (UMLS CUI [1,1])
C0750558 (UMLS CUI [1,2])
C0750558 (UMLS CUI [1,2])
Comorbidity Study Subject Participation Status Excluded | Dysfunction Study Subject Participation Status Excluded | Substance Use Disorders Study Subject Participation Status Excluded | Physical Examination Study Subject Participation Status Excluded | Laboratory finding Study Subject Participation Status Excluded
Item
has any other disease, dysfunction (including alcohol or drug abuse), physical examination or laboratory finding which, in the investigator's opinion, would exclude the participant from the study
boolean
C0009488 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])
C3887504 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C0332196 (UMLS CUI [2,3])
C0038586 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C0332196 (UMLS CUI [3,3])
C0031809 (UMLS CUI [4,1])
C2348568 (UMLS CUI [4,2])
C0332196 (UMLS CUI [4,3])
C0587081 (UMLS CUI [5,1])
C2348568 (UMLS CUI [5,2])
C0332196 (UMLS CUI [5,3])
C2348568 (UMLS CUI [1,2])
C0332196 (UMLS CUI [1,3])
C3887504 (UMLS CUI [2,1])
C2348568 (UMLS CUI [2,2])
C0332196 (UMLS CUI [2,3])
C0038586 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C0332196 (UMLS CUI [3,3])
C0031809 (UMLS CUI [4,1])
C2348568 (UMLS CUI [4,2])
C0332196 (UMLS CUI [4,3])
C0587081 (UMLS CUI [5,1])
C2348568 (UMLS CUI [5,2])
C0332196 (UMLS CUI [5,3])